Search PubMedSearch

PubMed · 10021758

Learning to control the program evolution process with cultural algorithms

Abstract

Traditional software engineering dictates the use of modular and structured programming and top-down stepwise refinement techniques that reduce the amount of variability arising in the development process by establishing standard procedures to be followed while writing software. This focusing leads to reduced variability in the resulting products, due to the use of standardized constructs. Genetic programming (GP) performs heuristic search in the space of programs. Programs produced through the GP paradigm emerge as the result of simulated evolution and are built through a bottom-up process, incrementally augmenting their functionality until a satisfactory level of performance is reached. Can we automatically extract knowledge from the GP programming process that can be useful to focus the search and reduce product variability, thus leading to a more effective use of the available resources? An answer to this question is investigated with the aid of cultural algorithms. A new system, cultural algorithms with genetic programming (CAGP), is presented. The system has two levels. The first is the pool of genetic programs (population level), and the second is a knowledge repository (belief set) that is built during the GP run and is used to guide the search process. The microevolution within the population brings about potentially meaningful characteristics of the programs for the achievement of the given task, such as properties exhibited by the best performers in the population. CAGP extracts these features and represents them as the set of the current beliefs. Beliefs correspond to constraints that all the genetic operators and programs must follow. Interaction between the two levels occurs in one direction through the extraction process and, in the other, through the modulation of an individual's program parameters according to which, and how many, of the constraints it follows. CAGP is applied to solve an instance of the symbolic regression problem, in which a function of one variable needs to be discovered. The results of the experiments show an overall improvement on the average performance of CAGP over GP alone and a significant reduction of the complexity of the produced solution. Moreover, the execution time required by CAGP is comparable with the time required by GP alone.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Zannoni, RG Reynolds. 1997. Learning to control the program evolution process with cultural algorithms. https://doi.org/10.1162/evco.1997.5.2.181

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article